Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

797 ARTÍCULOS , VIENDO DEL 526 AL 540

Evaluating computational and experimental approaches in early-stage Alzheimer's drug discovery: a systematic review

Azmal M, Paul JK, Shohan MNH, Haque ANMSNB, Mrinmoy M, Talukder OF, Ghosh A.

J Comput Aided Mol Des. 2025 Jun 6;39(1):27. doi: 10.1007/s10822-025-00610-7.

Role of 11β-Hydroxysteroid Dehydrogenase and Mineralocorticoid Receptor on Alzheimer's Disease Onset: A Systematic Review

Di Vincenzo M, Pellegrino P, Schiappa G, Campanati A, Del Vescovo V, Piccirillo S, Ambrogini P, Arnaldi G, Orciani M.

Int J Mol Sci. 2025 Feb 6;26(3):1357. doi: 10.3390/ijms26031357.

Efficacy and molecular mechanisms of hesperidin in mitigating Alzheimer's disease: A systematic review

Han X, Zhang Y, Zhang L, Zhuang Y, Wang Y.

Eur J Med Chem. 2025 Feb 5;283:117144. doi: 10.1016/j.ejmech.2024.117144. Epub 2024 Dec 4.

Differential effects of antidepressants on cognition in Alzheimer's disease with depression: A sub-group analysis of an open-label, observational study

Cumbo E, Migliore D.

J Alzheimers Dis. 2025 Jul;106(1):271-279. doi: 10.1177/13872877251340084. Epub 2025 May 7.

AdipoRon's Impact on Alzheimer's Disease-A Systematic Review and Meta-Analysis

Barbalho SM, Laurindo LF, de Oliveira Zanuso B, da Silva RMS, Gallerani Caglioni L, Nunes Junqueira de Moraes VBF, Fornari Laurindo L, Dogani Rodrigues V, da Silva Camarinha Oliveira J, Beluce ME, Penteado Detregiachi CR, Barbalho Lamas C, Dos Santos Haber JF, Cavallari Strozze Catharin VM, Quesada K, Tanaka M, Valenti VE.

Int J Mol Sci. 2025 Jan 8;26(2):484. doi: 10.3390/ijms26020484.

Phytochemical regulation of CaMKII in Alzheimer's disease: A review of molecular mechanisms and therapeutic potential

Lin Z, Sun M.

Pharmacol Res. 2025 Jun;216:107790. doi: 10.1016/j.phrs.2025.107790. Epub 2025 May 21.

Effectiveness of acupuncture combined with donepezil for Alzheimer's disease: A systematic review and meta-analysis

Wu Y, Zhan Y, Zhu W, Pei J.

Medicine (Baltimore). 2025 Jun 6;104(23):e42651. doi: 10.1097/MD.0000000000042651.

Implication for Clinical Trials From Longitudinal Tau-PET Accumulation Across Biological Alzheimer Disease Stages

Trudel L, Therriault J, Macedo AC, Servaes S, Hosseini SA, Bezgin G, Aumont E, Rahmouni N, Fernandez Arias J, Zheng Y, Wang YT, Chan T, Hall BJ, Hopewell R, Hsiao CH, Ferreira PCL, Bellaver B, Vitali P, Soucy JP, Pascoal TA, Gauthier S, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2025 Oct 21;105(8):e214111. doi: 10.1212/WNL.0000000000214111. Epub 2025 Sep 23.

Therapeutic implications of allopregnanolone in Alzheimer's related depression

Tidke B, Itekar S, Khobragade R, Vinchurney M, Trivedi R, Taksande B, Umekar M.

Behav Brain Res. 2025 Oct 18;495:115785. doi: 10.1016/j.bbr.2025.115785. Epub 2025 Aug 23.

The impact of rare genetic variants on Alzheimer disease

De Deyn L, Sleegers K.

Nat Rev Neurol. 2025 Mar;21(3):127-139. doi: 10.1038/s41582-025-01062-1. Epub 2025 Feb 4.

ABBV-552 in patients with mild Alzheimer's disease: a randomized phase IIb trial

Lynch SY, Jia J, Miles N, Boiser J, Buhl DL, Graff O, Zadikoff C.

Alzheimers Dement. 2025 Dec;21(12):e70994. doi: 10.1002/alz.70994.

Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease

Cummings J, Cohen S, Murphy J, Brothers HM, Nejati M, Forrestal F, de Moor C, O'Gorman J, Harrison J, Jaeger J, Mummery CJ, Porsteinsson AP, Potashman M, Tian Y, Yang L, He P, Haeberlein SB.

Alzheimers Dement. 2025 Jun;21(6):e70224. doi: 10.1002/alz.70224.

Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease

Chen CD, Franklin EE, Li Y, Joseph-Mathurin N, Burns AL, Hobbs DA, McCullough AA, Schultz SA, Xiong C, Wang G, Masellis M, Hsiung GR, Gauthier S, Berman SB, Roberson ED, Honig LS, Clarnette R, Ringman JM, Galvin JE, Brooks W, Suzuki K, Black S, Levin J, Aggarwal NT, Jucker M, Frosch MP, Kofler JK, White C 3rd, Keene CD, Chen J, Daniels A, Gordon BA, Ibanez L, Karch CM, Llibre-Guerra J, McDade E, Morris JC, Supnet-Bell C, Allegri RF, Lee JH, Day GS, Lopera F, Roh JH, Schofield PR, Mills S, Benzinger TLS, Bateman RJ, Perrin RJ; DIAN-TU Study Team; DIAN-Obs Study Team.

Acta Neuropathol. 2025 Jun 3;149(1):57. doi: 10.1007/s00401-025-02890-7.

Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study

Boon BDC, Piura YD, Moloney CM, Chalk JL, Lincoln SJ, Rutledge MH, Rothberg DM, Kouri N, Hinkle KM, Roemer SF, Johnson DR, Burkett BJ, Lowe VJ, Petersen RC, Dickson DW, Reichard RR, Nguyen AT, Graff-Radford J, Knopman DS, Graff-Radford NR, Murray ME.

Lancet Neurol. 2025 Nov;24(11):931-944. doi: 10.1016/S1474-4422(25)00313-8.

Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial

Burns JM, Morris JK, Vidoni ED, Wilkins HM, Choi IY, Lee P, Hunt SL, Mahnken JD, Brooks WM, Lepping RJ, Gupta A, Esterline R, Oscarsson J, Swerdlow RH.

Alzheimers Dement. 2025 Jun;21(6):e70416. doi: 10.1002/alz.70416.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias